Prokarium Ltd is a clinical stage SME with a dual business model: Out-licensing of its Vaxonella oral vaccine delivery platform, as well as development of in-house oral vaccines, currently a dual diarrhoea and typhoid vaccine as well as a Clostridium difficile vaccine. Prokarium raised Series A financing from Flerie Invest AB and is now progressing to its first clinical trial on Typhetec with results expected Dec 2015. Prokarium is interested in meeting with investors for a £2-12 million Series B financing during 2015.

If you are interested to know more about investing in Prokarium, please take a look at the following presentation and/or contact us to receive more detailed information:

Prokarium Investment Opportunity 17 Sep 2014

Old files with audio accompaniment (Team has changed, newer data now available):

Prokarium Presentation 7 Jan 2014

Audio 1 Prokarium Company Overview and Technologies

Audio 2a Prokarium Products Markets and Competitive Advantages

Audio 2b Prokarium Page 19 and onwards

Audio 3 Prokarium Clinical Development and Conclusion

Partnering with organisations interested in using the Vaxonella® platform is also a priority for Prokarium. If you have a vaccine candidate that you want to evaluate in an oral vaccine delivery platform, with the advantages of a single manufacturing platform, strong mucosal immune response and ease of manufacture, then we can offer to clone your antigens quickly and cheaply into our platform for you to evaluate in your established preclinical models. For more details on the advantages of oral delivery using Vaxonella, see the Technology section.